Revance Therapeutics Investor Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Revance Therapeutics To Contact Him Directly To Discuss Their Options
New York, New York--(Newsfile Corp. - November 30, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Revance Therapeutics, Inc. ("Revance Therapeutics" or the "Company") (NASDAQ: RVNC).
If you suffered losses exceeding $50,000 investing in Revance Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: http://www.faruqilaw.com/RVNC.
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
On October 15, 2021, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Revance Therapeutics, Inc., citing deficiencies found during an inspection at the Company's manufacturing facility for its wrinkle injection treatment, DaxibotulinumtoxinA, or DAXI (a competing product to BOTOX). Shares fell over 30% in after hours trading on October 15, 2021 following news of the FDA letter. Previously, shares of Revance Therapeutics fell over 25% in intraday trading on October 12, 2021 after Form 483 was posted to the FDA's website.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106005